Michael Tung Takes on CFO Role to Propel vTv Therapeutics Forward
Michael Tung Steps in as CFO of vTv Therapeutics
vTv Therapeutics Inc. (NASDAQ: VTVT), a prominent biopharmaceutical company focused on innovative treatments, has announced the appointment of Michael Tung, M.D., MBA, as its Chief Financial Officer. This critical leadership change aims to bolster the company’s financial strategies as it progresses with its clinical trials for an important diabetes medication.
Bringing Wealth of Experience
Dr. Tung joins vTv Therapeutics with over 20 years of extensive experience in finance, strategic management, and investor relations specifically within the biopharmaceutical landscape. His past roles demonstrate his ability to navigate complex financial situations, underscoring his readiness to contribute to vTv at such a pivotal moment. His appointment is instrumental as the company resumes its CATT1 Phase 3 trial of cadisegliatin, a promising oral adjunctive therapy for type 1 diabetes.
Comment from the CEO
Paul Sekhri, the Chairman and CEO of vTv Therapeutics, expressed enthusiasm about the new addition to their executive team. According to Sekhri, Dr. Tung's expertise will be vital in shaping the company’s financial strategy and maintaining strong relationships within the financial community to benefit the ongoing projects.
Dr. Tung's Vision at vTv
Expressing his excitement, Dr. Tung stated his commitment to support vTv as it advances its clinical initiatives. He emphasizes the importance of enhancing shareholder value while achieving the company’s strategic goals. With his unique combination of medical and business acumen, Dr. Tung is poised to make significant contributions to vTv’s mission.
A Track Record in Finance
Before joining vTv Therapeutics, Dr. Tung served as the Chief Financial Officer at AdvanCell Pty Limited, where he played a vital role in improving financial management and strategic direction. He has also held key positions at FibroGen Inc. and Aclaris Therapeutics, where he honed his skills in corporate strategy and investor relations.
About vTv Therapeutics
vTv Therapeutics is dedicated to developing cutting-edge therapies aimed at revolutionizing treatment options for chronic diseases, particularly diabetes. One of its leading candidates, cadisegliatin, is currently undergoing a Phase 3 trial, representing a potential breakthrough in oral treatments for type 1 diabetes. The company is actively exploring various drug candidates targeting multiple indications, focusing on enhancing the quality of life for patients.
What is Cadisegliatin?
Cadisegliatin (TTP399) is a novel oral small molecule that selectively activates glucokinase in the liver, aiming to improve glycemic control by enhancing hepatic glucose uptake and glycogen storage. The ongoing clinical trials are crucial to establishing the efficacy and safety profile of this promising therapy, but success is not guaranteed.
Contact Information for vTv Therapeutics
For investors looking for more information or to engage with the company, Sandya von der Weid from LifeSci Advisors can be reached at svonderweid@lifesciadvisors.com. Additionally, media inquiries can be directed to Caren Begun at TellMed Strategies via phone at 201-396-8551 or email at caren.begun@tmstrat.com.
Frequently Asked Questions
What is the focus of vTv Therapeutics?
vTv Therapeutics specializes in developing oral drug candidates for chronic diseases, particularly diabetes.
Who is Michael Tung?
Michael Tung, M.D., MBA, is the newly appointed Chief Financial Officer of vTv Therapeutics, bringing over 20 years of industry experience.
What is cadisegliatin?
Cadisegliatin is an investigational oral therapy designed to improve glycemic control for patients with type 1 diabetes.
How can investors contact vTv Therapeutics?
Investors can reach out to Sandya von der Weid at LifeSci Advisors via email.
What is the current status of the CATT1 Phase 3 trial?
The CATT1 Phase 3 trial for cadisegliatin has been reinitiated and is currently screening participants.
About The Author
Contact Thomas Cooper privately here. Or send an email with ATTN: Thomas Cooper as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
